Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated ...

Chemomab Therapeutics (CMMB) announced the successful completion of its End-of-Phase 2 Meeting with the FDA and alignment with FDA on the ...

Crohns disease is a chronic Inflammatory Bowel Disease IBD which produces persistent irritation of the gastrointestinal tract ...

Tod Lashway had questions about his wife’s chronic disease and discovered he could possibly be the donor she desperately ...

Last February, Pliant Therapeutics released 12-week interim data from the 320 mg dose group of INTEGRIS-PSC Phase 2a trial of ...

Maxim raised the firm’s price target on Chemomab Therapeutics (CMMB) to $7 from $4 and keeps a Buy rating on the shares. The firm cites the ...

The inflammatory bowel disease (IBD), develops due to an incurable autoimmune liver disease called primary sclerosing ...

Reference: Quraishi MN, Cheesbrough J, Rimmer P, et al. Open label vancomycin in primary sclerosing cholangitis-inflammatory ...

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated with primary sclerosing cholangitis, according to a study published in ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...